Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Intron in Resectable Head and Neck Cancer
NCT00276523Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2004
- Primary completion
- Mar 2006
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peginterferon alfa-2b in head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Response Rate at 3 weeks, Microvessel Density (MVD) and 2 more. Started Feb 2004; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00276523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276523.